EPISODE · May 28, 2026 · 5 MIN
EQ-5D-5L Update Reshapes Cancer Economics
Episode 14 — 28 May 2026 NICE's first QALY valuation update in over a decade shows cancer medicines becoming more cost-effective while quality-of-life therapies face higher ICERs. Meanwhile, JCA expansion into medical devices and new NICE prioritisation frameworks signal tighter evidence requirements across the board. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Embed this episode
NOW PLAYING
EQ-5D-5L Update Reshapes Cancer Economics
0:00
5:34
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Carl Haakon's Podcast?
This episode is 5 minutes long.
When was this Carl Haakon's Podcast episode published?
This episode was published on May 28, 2026.
Can I download this Carl Haakon's Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!